Advances in detection and characterization of atherosclerosis using contrast agents targeting the macrophage

Journal of Nuclear Cardiology

Volumn 13, Issue 5, 2006, Pages 699-709

  Lipinski, Michael J ^a   Frias, Juan Carlos ^b   Fayad, Zahi A ^c  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VALENCIA   (Spain)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE SERUM ALBUMIN; CHEMOKINE RECEPTOR CCR2; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; GADOLINIUM PENTETATE; GADOLINIUM TETRAAZACYCLODODECANETETRAACETIC ACID; HIGH DENSITY LIPOPROTEIN; MANGANESE DERIVATIVE; MATRIX METALLOPROTEINASE; MESOPORPHYRIN; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR; SUPERPARAMAGNETIC IRON OXIDE; TECHNETIUM 99M; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; ELECTRON SPIN RESONANCE; EX VIVO STUDY; HUMAN; MACROPHAGE; MICELLE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; ATHEROSCLEROSIS; CONTRAST MEDIA; FLUORODEOXYGLUCOSE F18; HUMANS; MACROPHAGES; MODELS, BIOLOGICAL; RADIOPHARMACEUTICALS;

EID: 33747822578     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nuclcard.2006.07.004     Document Type: Article

References (61)

1. Ambrose J.A., Tannenbaum M.A., Alexopoulos D., et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 12 (1988) 56-62
2. Little W.C., Constantinescu M., Applegate R.J., et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease?. Circulation 78 (1988) 1157-1166
3. Kannel W.B. Some lessons in cardiovascular epidemiology from Framingham. Am J Cardiol 37 (1976) 269-282
4. Davies M.J., Richardson P.D., Woolf N., Katz D.R., and Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 69 (1993) 377-381
5. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
6. Malek A.M., Alper S.L., and Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA 282 (1999) 2035-2042
7. McGill Jr. H.C. Fatty streaks in the coronary arteries and aorta. Lab Invest 18 (1968) 560-564
8. Kinlay S., Libby P., and Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol 12 (2001) 383-389
9. Cushing S., Berliner J., Valente A., et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A 87 (1990) 5134-5138
10. Gosling J., Slaymaker S., Gu L., et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 103 (1999) 773-778
11. Boring L., Gosling J., Cleary M., and Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394 (1998) 894-897
12. Dansky H.M., Barlow C.B., Lominska C., et al. Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage. Arterioscler Thromb Vasc Biol 21 (2001) 1662-1667
13. Moreno P.R., Purushothaman K.R., Sirol M., Levy A.P., and Fuster V. Neovascularization in human atherosclerosis. Circulation 113 (2006) 2245-2252
14. O'Brien K.D., McDonald T.O., Chait A., Allen M.D., and Alpers C.E. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 93 (1996) 672-682
15. Goldstein J.L., Ho Y.K., Basu S.K., and Brown M.S. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A 76 (1979) 333-337
16. Krieger M., Abrams J.M., Lux A., and Steller H. Molecular flypaper, atherosclerosis, and host defense: structure and function of the macrophage scavenger receptor. Cold Spring Harb Symp Quant Biol 57 (1992) 605-609
17. Hamilton J.A., Myers D., Jessup W., et al. Oxidized LDL can induce macrophage survival, DNA synthesis, and enhanced proliferative response to CSF-1 and GM-CSF. Arterioscler Thromb Vasc Biol 19 (1999) 98-105
18. Richardson P.D., Davies M.J., and Born G.V. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 2 (1989) 941-944
19. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 50 (1983) 127-134
20. Matrisian L.M. The matrix-degrading metalloproteinases. Bioessays 14 (1992) 455-463
21. Zingg J.M., Ricciarelli R., and Azzi A. Scavenger receptors and modified lipoproteins: fatal attractions?. IUBMB Life 49 (2000) 397-403
22. Araki N., Higashi T., Mori T., et al. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur J Biochem 230 (1995) 408-415
23. Boullier A., Bird D.A., Chang M.K., et al. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann N Y Acad Sci 947 (2001) 214-222 discussion 222-3
24. Gough P.J., Greaves D.R., Suzuki H., et al. Analysis of macrophage scavenger receptor (SR-A) expression in human aortic atherosclerotic lesions. Arterioscler Thromb Vasc Biol 19 (1999) 461-471
25. Babaev V.R., Gleaves L.A., Carter K.J., et al. Reduced atherosclerotic lesions in mice deficient for total or macrophage-specific expression of scavenger receptor-A. Arterioscler Thromb Vasc Biol 20 (2000) 2593-2599
26. Sakaguchi H., Takeya M., Suzuki H., et al. Role of macrophage scavenger receptors in diet-induced atherosclerosis in mice. Lab Invest 78 (1998) 423-434
27. Suzuki H., Kurihara Y., Takeya M., et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 386 (1997) 292-296
28. Febbraio M., Podrez E.A., Smith J.D., et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 105 (2000) 1049-1056
29. Nakata A., Nakagawa Y., Nishida M., et al. CD36, a novel receptor for oxidized low-density lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta. Arterioscler Thromb Vasc Biol 19 (1999) 1333-1339
30. Lipinski M.J., Amirbekian V., Frias J.C., et al. MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med (2006) Aug 10 [E pub ahead of print]
31. Lipinski M.J., Frias J.C., Aguinaldo J.G.S., et al. Macrophage detection in atherosclerotic plaque using gadolinium-containing immunomicelles and MRI. American Heart Association Scientific Session (2004), Circulation, New Orleans [abstract] 663
32. Amirbekian V., Amirbekian S., Lipinski M.J., Aguinaldo J.G.S., Frias J.C., and Fayad Z.A. MR imaging (in vivo) of apo-E -/- mice to assess atherosclerosis with gadolinium-containing micelles and immunomicelles molecularly targeted to macrophages. Proceedings of the Radiological Society of North America (RSNA) (2005) Chicago, Ill, [abstract] SSA11-02
33. Gustafsson B., Youens S., and Louie A.Y. Development of contrast agents targeted to macrophage scavenger receptors for MRI of vascular inflammation. Bioconjug Chem 17 (2006) 538-547
34. Lees A.M., Lees R.S., Schoen F.J., et al. Imaging human atherosclerosis with 99mTc-labeled low density lipoproteins. Arteriosclerosis 8 (1988) 461-470
35. Iuliano L., Mauriello A., Sbarigia E., Spagnoli L.G., and Violi F. Radiolabeled native low-density lipoprotein injected into patients with carotid stenosis accumulates in macrophages of atherosclerotic plaque: effect of vitamin E supplementation. Circulation 101 (2000) 1249-1254
36. Gurudutta G.U., Babbar A.K., Shailaja S., Soumya P., and Sharma R.K. Evaluation of potential tracer ability of (99m)Tc-labeled acetylated LDL for scintigraphy of LDL-scavenger receptor sites of macrophageal origin. Nucl Med Biol 28 (2001) 235-241
37. Mitsumori L.M., Ricks J.L., Rosenfeld M.E., Schmiedl U.P., and Yuan C. Development of a lipoprotein based molecular imaging MR contrast agent for the noninvasive detection of early atherosclerotic disease. Int J Cardiovasc Imaging 20 (2004) 561-567
38. Frias J.C., Williams K.J., Fisher E.A., and Fayad Z.A. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 126 (2004) 16316-16317
39. Krieger M. Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest 108 (2001) 793-797
40. Acton S., Rigotti A., Landschulz K.T., Xu S., Hobbs H.H., and Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271 (1996) 518-520
41. Cuchel M., and Rader D.J. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?. Circulation 113 (2006) 2548-2555
42. Benderbous S., Corot C., Jacobs P., and Bonnemain B. Superparamagnetic agents: physicochemical characteristics and preclinical imaging evaluation. Acad Radiol 3 Suppl 2 (1996) S292-S294
43. Weissleder R., Elizondo G., Wittenberg J., Rabito C., Bengele H., and Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 175 (1990) 489-493
44. Saini S., Stark D., Hahn P., Wittenberg J., Brady T., and Ferrucci Jr. J. Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system. Radiology 162 (1987) 211-216
45. Raynal I., Prigent P., Peyramaure S., Najid A., Rebuzzi C., and Corot C. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol 39 (2004) 56-63
46. Ruehm S.G., Corot C., Vogt P., Kolb S., and Debatin J.F. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 103 (2001) 415-422
47. Litovsky S., Madjid M., Zarrabi A., Casscells S.W., Willerson J.T., and Naghavi M. Superparamagnetic iron oxide-based method for quantifying recruitment of monocytes to mouse atherosclerotic lesions in vivo: enhancement by tissue necrosis factor-alpha, interleukin-1beta, and interferon-gamma. Circulation 107 (2003) 1545-1549
48. Schmitz S.A., Coupland S.E., Gust R., et al. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest Radiol 35 (2000) 460-471
49. Hyafil F., Laissy J.P., Mazighi M., et al. Ferumoxtran-10-enhanced MRI of the hypercholesterolemic rabbit aorta: relationship between signal loss and macrophage infiltration. Arterioscler Thromb Vasc Biol 26 (2006) 176-181
50. Kooi M.E., Cappendijk V.C., Cleutjens K.B., et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 107 (2003) 2453-2458
51. Trivedi R.A., Mallawarachi C., U-King-Im J.M., et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol 26 (2006) 1601-1606
52. Siglienti I., Bendszus M., Kleinschnitz C., and Stoll G. Cytokine profile of iron-laden macrophages: implications for cellular magnetic resonance imaging. J Neuroimmunol 173 (2006) 166-173
53. Mani V., Briley-Saebo K.C., Itskovich V.V., Samber D.D., and Fayad Z.A. Gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP): sequence characterization in membrane and glass superparamagnetic iron oxide phantoms at 1.5T and 3T. Magn Reson Med 55 (2006) 126-135
54. Davies J.R., Rudd J.H., Weissberg P.L., and Narula J. Radionuclide imaging for the detection of inflammation in vulnerable plaques. J Am Coll Cardiol 47 (2006) C57-C68
55. Yun M., Yeh D., Araujo L.I., Jang S., Newberg A., and Alavi A. F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med 26 (2001) 314-319
56. Lederman R.J., Raylman R.R., Fisher S.J., et al. Detection of atherosclerosis using a novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG). Nucl Med Commun 22 (2001) 747-753
57. Rudd J.H., Warburton E.A., Fryer T.D., et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 105 (2002) 2708-2711
58. Davies J.R., Rudd J.H.F., Fryer T.D., et al. Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke 36 (2005) 2642-2647
59. Dunphy M.P., Freiman A., Larson S.M., and Strauss H.W. Association of vascular 18F-FDG uptake with vascular calcification. J Nucl Med 46 (2005) 1278-1284
60. Matter C.M., Wyss M.T., Meier P., et al. 18F-choline images murine atherosclerotic plaques ex vivo. Arterioscler Thromb Vasc Biol 26 (2006) 584-589
61. Lipinski M.J., Fuster V., Fisher E.A., and Fayad Z.A. Technology insight: targeting of biological molecules for evaluation of high-risk atherosclerotic plaques with magnetic resonance imaging. Nat Clin Pract Cardiovasc Med 1 (2004) 48-55